Corcept Therapeutics
CORT
422 hedge funds and large institutions have $9.24B invested in Corcept Therapeutics in 2025 Q1 according to their latest regulatory filings, with 103 funds opening new positions, 129 increasing their positions, 144 reducing their positions, and 41 closing their positions.
220% more funds holding in top 10
Funds holding in top 10: 5 → 16 (+11)
151% more first-time investments, than exits
New positions opened: 103 | Existing positions closed: 41
118% more capital invested
Capital invested by funds: $4.25B → $9.24B (+$5B)
15% more funds holding
Funds holding: 367 → 422 (+55)
1.56% less ownership
Funds ownership: 80.42% → 78.86% (-1.6%)
10% less repeat investments, than reductions
Existing positions increased: 129 | Existing positions reduced: 144
42% less call options, than puts
Call options by funds: $193M | Put options by funds: $335M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$36.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$32.9M |
| 3 |
Man Group
London,
United Kingdom
|
+$20.8M |
| 4 |
Morgan Stanley
New York
|
+$16.9M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$60.2M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
-$21.7M |
| 3 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
-$19.1M |
| 4 |
SAM
Synergy Asset Management
Vancouver,
Washington
|
-$17.8M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$17.7M |
CORT Hedge Fund Activity: Q1 2025 in Review
422 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q1 2025, worth a combined $9.24B — up 118% from $4.25B a quarter earlier.
Buyers outnumbered sellers: 103 funds opened new CORT positions and 41 closed out — a net gain of 62 holders — while 129 added to existing stakes and 144 trimmed.
The largest buyer was Jupiter Asset Management, adding an estimated $36.3M. The largest seller was BlackRock, cutting an estimated $60.2M.
- 422 institutional investors held Corcept Therapeutics (CORT) as of Q1 2025, up from 367 in Q4 2024.
- Funds reported $9.24B of Corcept Therapeutics stock for Q1 2025, up 118% quarter-over-quarter.
- 103 funds opened new Corcept Therapeutics positions in Q1 2025 and 41 closed out, a net change of +62 holders.
- The largest Corcept Therapeutics buyer in Q1 2025 was Jupiter Asset Management, an estimated $36.3M added.
- The largest Corcept Therapeutics seller in Q1 2025 was BlackRock, an estimated $60.2M sold.
Based on aggregated 13F filings for Q1 2025.